医学
子宫腺肌病
子宫内膜异位症
子宫内膜增生
不育
子宫肌瘤
左炔诺孕酮
妇科
产科
子宫内膜癌
宫内节育器
子宫内膜
怀孕
人口
计划生育
内科学
癌症
研究方法
环境卫生
生物
遗传学
出处
期刊:Contraception
[Elsevier]
日期:2007-06-01
卷期号:75 (6): S112-S117
被引量:17
标识
DOI:10.1016/j.contraception.2006.12.013
摘要
Progestins delivered by a variety of routes have been demonstrated, in addition to their high contraceptive effect, to have substantial benefits in the treatment of various gynecological disorders, and the intrauterine route has particular efficacy in treating endometrial and myometrial disorders. It should be possible to extend this to prevention of disease.Those conditions for which there is most evidence of therapeutic benefit from intrauterine release of progestins include heavy menstrual bleeding (due to most causes), endometrial hyperplasia, endometriosis and adenomyosis.Reasonable evidence exists to support the findings that intrauterine levonorgestrel helps to prevent the development of uterine fibroids, endometriosis, endometrial hyperplasia, acute episodes of pelvic infection and a wide range of menstrual symptoms. There is also promise of prevention of endometrial carcinoma, endometrial polyps, infertility and perhaps adenomyosis.There is a need for specific studies to further explore the prevention of these gynecological conditions which can cause major health disturbances and community distress.
科研通智能强力驱动
Strongly Powered by AbleSci AI